Nutritional Status of Adults with Phenylketonuria on Pegvaliase: A 15-month Prospective Study

Overview

Journal Mol Genet Metab Rep

Specialty Endocrinology

Date 2023 Dec 6

PMID 38053931

Authors

Krista Viau

Leslie Martell

Ann Wessel

Fran Rohr

Suzanne Hollander

Melissa S Putman

Stephanie Sacharow

Affiliations

Soon will be listed here.

Abstract

Background: Pegvaliase has allowed many adults with phenylketonuria (PKU) to achieve acceptable blood Phe control while eating an unrestricted diet. However, little is known about potential differences in nutritional status and eating behaviors after transitioning from a phenylalanine (Phe)-restricted to an unrestricted diet. Here we assessed change in nutritional status in adults with early-treated PKU who were consuming a Phe-restricted diet (intact protein ≤0.8 g/kg/day) prior to starting pegvaliase.

Methods: A 15-month, prospective, longitudinal study to assess change in anthropometrics, dietary intake, laboratory indices of nutritional status, bone mineral density (BMD), body composition, measured resting energy expenditure (REE), and eating behaviors between baseline and Month 15.

Results: Eleven adults ( = 7 female) aged 19.5-52.9 years completed the study. Six participants had a substantial blood Phe reduction (responders) and five participants had a modest blood Phe reduction (partial responders) by Month 15. Intact protein intake increased by an average of 49.4 g/day and 26.7 g/day in responders and partial responders, respectively. Plasma concentrations of most vitamins, minerals, and essential fatty acids assessed were normal, though micronutrient intakes decreased as participants decreased or discontinued PKU medical food(s). Responders had a more variable change in body mass index (BMI) and lean mass index (LMI) compared to partial responders, though there were no clear trends in BMD or body composition changes. Total protein intake was positively correlated with LMI. Responders, but not partial responders, self-reported increased in enjoyment of food and decreased food neophobia, uncontrolled eating, and emotional eating.

Discussion: Participants transitioning to an unrestricted diet while on pegvaliase maintained adequate nutritional status overall with no clinically significant changes in cardiovascular or glycemic markers. Responders reported improvements in eating behaviors, including reduced food neophobia, uncontrolled eating, and emotional eating, and increased enjoyment of food. There were no consistent trends in BMD, body composition, or BMI changes. A larger sample size and longer follow-up period are needed to further assess potential changes.

Citing Articles

Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase.

Stecchi M, Rossi A, Santoni M, Bandini F, Brodosi L Nutrients. 2024; 16(19).

PMID: 39408315 PMC: 11479136. DOI: 10.3390/nu16193348.

Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity.

Pinto A, Ahring K, Almeida M, Ashmore C, Belanger-Quintana A, Burlina A Nutrients. 2024; 16(17).

PMID: 39275225 PMC: 11396810. DOI: 10.3390/nu16172909.

References

Huemer M, Huemer C, Moslinger D, Huter D, Stockler-Ipsiroglu S . Growth and body composition in children with classical phenylketonuria: results in 34 patients and review of the literature. J Inherit Metab Dis. 2007; 30(5):694-9. DOI: 10.1007/s10545-007-0549-3. View

Burton B, Jones K, Cederbaum S, Rohr F, Waisbren S, Irwin D . Prevalence of comorbid conditions among adult patients diagnosed with phenylketonuria. Mol Genet Metab. 2018; 125(3):228-234. DOI: 10.1016/j.ymgme.2018.09.006. View

Cunningham J . Body composition as a determinant of energy expenditure: a synthetic review and a proposed general prediction equation. Am J Clin Nutr. 1991; 54(6):963-9. DOI: 10.1093/ajcn/54.6.963. View

Trefz K, Muntau A, Kohlscheen K, Altevers J, Jacob C, Braun S . Clinical burden of illness in patients with phenylketonuria (PKU) and associated comorbidities - a retrospective study of German health insurance claims data. Orphanet J Rare Dis. 2019; 14(1):181. PMC: 6647060. DOI: 10.1186/s13023-019-1153-y. View

Garaulet M, Canteras M, Morales E, Lopez-Guimera G, Sanchez-Carracedo D, Corbalan-Tutau M . Validation of a questionnaire on emotional eating for use in cases of obesity: the Emotional Eater Questionnaire (EEQ). Nutr Hosp. 2012; 27(2):645-51. DOI: 10.1590/S0212-16112012000200043. View

Jarnes Utz J, Lorentz C, Markowitz D, Rudser K, Diethelm-Okita B, Erickson D . START, a double blind, placebo-controlled pharmacogenetic test of responsiveness to sapropterin dihydrochloride in phenylketonuria patients. Mol Genet Metab. 2011; 105(2):193-7. DOI: 10.1016/j.ymgme.2011.10.014. View

Longo N, Dimmock D, Levy H, Viau K, Bausell H, Bilder D . Evidence- and consensus-based recommendations for the use of pegvaliase in adults with phenylketonuria. Genet Med. 2018; 21(8):1851-1867. PMC: 6752676. DOI: 10.1038/s41436-018-0403-z. View

Sacharow S, Papaleo C, Almeida K, Goodlett B, Kritzer A, Levy H . First 1.5 years of pegvaliase clinic: Experiences and outcomes. Mol Genet Metab Rep. 2020; 24:100603. PMC: 7256053. DOI: 10.1016/j.ymgmr.2020.100603. View

Pliner P, Hobden K . Development of a scale to measure the trait of food neophobia in humans. Appetite. 1992; 19(2):105-20. DOI: 10.1016/0195-6663(92)90014-w. View

10.

Lah M, Cook K, Gomes D, Liu S, Tabatabaeepour N, Kirson N . Real-world treatment, dosing, and discontinuation patterns among patients treated with pegvaliase for phenylketonuria: Evidence from dispensing data. Mol Genet Metab Rep. 2022; 33:100918. PMC: 9513695. DOI: 10.1016/j.ymgmr.2022.100918. View

11.

Hollander S, Viau K, Sacharow S . Pegvaliase dosing in adults with PKU: Requisite dose for efficacy decreases over time. Mol Genet Metab. 2022; 137(1-2):104-106. DOI: 10.1016/j.ymgme.2022.08.001. View

12.

Hochuli M, Bollhalder S, Thierer C, Refardt J, Gerber P, Baumgartner M . Effects of Inadequate Amino Acid Mixture Intake on Nutrient Supply of Adult Patients with Phenylketonuria. Ann Nutr Metab. 2017; 71(3-4):129-135. DOI: 10.1159/000479746. View

13.

Cunningham A, Rohr F, Splett P, Mofidi S, Bausell H, Stembridge A . Nutrition management of PKU with pegvaliase therapy: update of the web-based PKU nutrition management guideline recommendations. Orphanet J Rare Dis. 2023; 18(1):155. PMC: 10288765. DOI: 10.1186/s13023-023-02751-0. View

14.

da Silva W, Campos J, Maroco J . Impact of inherent aspects of body image, eating behavior and perceived health competence on quality of life of university students. PLoS One. 2018; 13(6):e0199480. PMC: 6014647. DOI: 10.1371/journal.pone.0199480. View

15.

Viau K, Wessel A, Martell L, Sacharow S, Rohr F . Nutrition status of adults with phenylketonuria treated with pegvaliase. Mol Genet Metab. 2021; 133(4):345-351. DOI: 10.1016/j.ymgme.2021.06.002. View

16.

Evans S, Daly A, Chahal S, Macdonald J, Macdonald A . Food acceptance and neophobia in children with phenylketonuria: a prospective controlled study. J Hum Nutr Diet. 2015; 29(4):427-33. DOI: 10.1111/jhn.12346. View

17.

Cornil Y, Chandon P . Pleasure as an ally of healthy eating? Contrasting visceral and Epicurean eating pleasure and their association with portion size preferences and wellbeing. Appetite. 2015; 104:52-9. DOI: 10.1016/j.appet.2015.08.045. View

18.

Jurecki E, Cederbaum S, Kopesky J, Perry K, Rohr F, Sanchez-Valle A . Adherence to clinic recommendations among patients with phenylketonuria in the United States. Mol Genet Metab. 2017; 120(3):190-197. DOI: 10.1016/j.ymgme.2017.01.001. View

19.

Vockley J, Andersson H, Antshel K, Braverman N, Burton B, Frazier D . Phenylalanine hydroxylase deficiency: diagnosis and management guideline. Genet Med. 2014; 16(2):188-200. DOI: 10.1038/gim.2013.157. View

20.

McWhorter N, Dhillon J, Hoffman J . Preliminary Investigation of Microbiome and Dietary Differences in Patients with Phenylketonuria on Enzyme Substitution Therapy Compared to Traditional Therapies. J Acad Nutr Diet. 2021; 122(7):1283-1295.e3. DOI: 10.1016/j.jand.2021.12.011. View